Sign In
Buy EXEL
$56.00
+0.94 (+1.71%)
At Close: Aug 04, 2026
Why Is Exelixis (EXEL) Down 0.6% Since Last Earnings Report?
12:38pm, Thursday, 08'th Jun 2023
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?
Exelixis: Thriving Investment Opportunity In The Evolving World Of Oncology
05:49am, Sunday, 28'th May 2023
Revenue-generating products like Cabometyx and strategic partnerships with industry leaders, such as Genentech, contribute to Exelixis' impressive financial performance and market presence. Exelixis'
2 Under-the-Radar Biotech Stocks to Buy in 2023
09:53am, Wednesday, 24'th May 2023
Exelixis and Sarepta are relatively small players in the highly competitive biotech industry. Both drugmakers have found success by focusing most of their efforts on niche areas.
2 Unstoppable Growth Stocks to Buy in 2023 and Beyond
09:30am, Saturday, 20'th May 2023
Axsome has several catalysts in the works that could boost its stock price. Exelixis is working on new drugs to expand its footprint in oncology.
Exelixis (EXEL) Q1 Earnings Miss, Revenues Increase Y/Y
03:59pm, Wednesday, 10'th May 2023
Exelixis (EXEL) misses first quarter 2023 earnings and sales estimates, but product sales increase year over year.
Compared to Estimates, Exelixis (EXEL) Q1 Earnings: A Look at Key Metrics
10:09pm, Tuesday, 09'th May 2023
The headline numbers for Exelixis (EXEL) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimat
Exelixis (EXEL) Lags Q1 Earnings and Revenue Estimates
08:37pm, Tuesday, 09'th May 2023
Exelixis (EXEL) came out with quarterly earnings of $0.16 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.21 per share a year ago.
Exelixis to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023
04:05pm, Tuesday, 25'th Apr 2023
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2023 financial results will be released on Tuesday, May 9, 2023 after the markets close. At 5:00
EXEL or ILMN: Which Is the Better Value Stock Right Now?
12:57pm, Tuesday, 25'th Apr 2023
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Illumina (ILMN). But which of these two stocks is more attractive to value investors?
Wall Street Analysts See a 36.54% Upside in Exelixis (EXEL): Can the Stock Really Move This High?
11:28am, Tuesday, 25'th Apr 2023
The consensus price target hints at a 36.5% upside potential for Exelixis (EXEL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
Farallon steps up activism at biotech company Exelixis. Here's what could happen next
07:26am, Saturday, 15'th Apr 2023
Farallon isn't an activist investor, but it won't shy away from a battle if necessary.
Exelixis (EXEL) Surges 25.4% so Far in 2023: Here's Why
02:34pm, Tuesday, 11'th Apr 2023
Exelixis' (EXEL) efforts to expand Cabometyx's label and develop additional drugs to expand its portfolio should reap rewards for the company.
2 Under-the-Radar Biotech Stocks to Buy in 2023
10:11am, Wednesday, 05'th Apr 2023
CRISPR Therapeutics' near-term outlook is quite bullish. There are more lucrative opportunities for Exelixis in the near future.
Farallon to launch proxy fight at biotech Exelixis: WSJ
06:23pm, Tuesday, 04'th Apr 2023
Hedge fund Farallon Capital Management plans to launch a proxy fight at cancer-drug maker Exelixis Inc. EXEL, +0.36% , and has nominated three directors to that company's board, the Wall Street Journa
Farallon Capital to Wage Proxy Battle at Biotech Firm
06:00pm, Tuesday, 04'th Apr 2023
Farallon has nominated three directors to the board of Exelixis, which develops cancer-fighting drugs.
